TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.MoreShow less
Profile & Fundamentals
Review the profile, reported financial history, AI financial assessment, dividends, splits, and dated events for TransMedics Group.
Profile & Fundamentals
TransMedics Group Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Company profile record
TransMedics Group Inc
Common Stock · Healthcare · Medical Devices
Company
- Company / asset
- TransMedics Group Inc
- Security type
- Common Stock
- Sector
- Healthcare
- Industry
- Medical Devices
- HQ
- 🇺🇸 United States
- Head office
- 200 Minuteman Road, Andover, MA, United States, 01810
Leadership & scale
- Chief executive
- Dr. Waleed H. Hassanein M.D.
- CEO year born
- 1968
- Full-time employees
- 898
- Fiscal year end
- December
- IPO date
- 2019-05-02
Fundamentals snapshot
- Market Cap
- USD 2.8B
- P/E
- 16.1x
- Revenue (Q1 26)
- USD 173.9M
- Profit (Q1 26)
- USD 7.3M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 605.5M
- Shares in public float
- 33.4M
- Insider ownership
- 3.65%
Reporting & identifiers
- Symbol
- TMDX.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US89377M1099
- Asset ID
- equity_d62d0544-c7ef-5aac-89a3-9c2c26cb704d
Ownership
Shares Outstanding
Latest: 36.2M | Max: 40.9M | Min: 4.7M
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open every chart, financial statement, event, and source table.